Zhuo Wang

Dr. Zhuo Wang

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
XHXiujuan Han
Xiujuan Han
CGChunai Gong
Chunai Gong
QYQingru Yang
Qingru Yang
KZKaile Zheng
Kaile Zheng
ZWZhuo Wang
Zhuo Wang
WZWei Zhang
Wei Zhang
With the development of nanotechnology, nanoparticles (NPs) have shown broad prospects as drug delivery vehicles. However, they exhibit certain limitations, including low biocompatibility, poor physiological stability, rapid clearance from the body, and nonspecific targeting, which have hampered their clinical application. Therefore, the development of novel drug delivery systems with improved biocompatibility and high target specificity remains a major challenge. In recent years, biofilm mediated biomimetic nano-drug delivery system (BNDDS) has become a research hotspot focus in the field of life sciences. This new biomimetic platform uses bio-nanotechnology to encapsulate synthetic NPswithin biomimetic membrane, organically integrating the low immunogenicity, low toxicity, high tumor targeting, good biocompatibility of the biofilm with the adjustability and versatility of the nanocarrier, and shows promising applications in the field of precision tumor therapy. In this review, we systematically summarize the new progress in BNDDS used for optimizing drug delivery, providing a theoretical reference for optimizing drug delivery and designing safe and efficient treatment strategies to improve tumor treatment outcomes.

29 October 2018 in Medical Science Monitor
Verified
Journal Article
Closed access
PDF file
YYYunyun Yang
Yunyun Yang
XWXuebin Wang
Xuebin Wang
JTJing Tian
Jing Tian
ZWZhuo Wang
Zhuo Wang
BACKGROUND:Methotrexate (MTX) is an effective drug for the treatment of adult malignancies, but toxicity remains a significant problem. Toxic reactions may occur when patients use high-dose MTX (HD-MTX), but the correlation between its toxicity and c...

15 July 2025 in Chinese Journal of Natural Medicines
Verified
Journal Article
Closed access
HYHaizheng Yu
Haizheng Yu
FLFen Lan
Fen Lan
YZYuan Zhuang
Yuan Zhuang
QLQizhang Li
Qizhang Li
LZLianqing Zhang
Lianqing Zhang
LZLei Zhang
Lei Zhang

30 May 2024 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
XWXuebin Wang
Xuebin Wang
ZLZhengyue Liu
Zhengyue Liu
JCJingxia Chen
Jingxia Chen
YCYuhui Chai
Yuhui Chai
XSXueqing Shao
Xueqing Shao
MFMeiqing Feng
Meiqing Feng

11 June 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
JYJia You
Jia You
RCRui Chen
Rui Chen
YCYuhui Chai
Yuhui Chai
XWXue Wang
Xue Wang
WXWenmin Xie
Wenmin Xie
XWXuebin Wang
Xuebin Wang
Background: Tacrolimus, a key immunosuppressant for kidney transplant recipients, is traditionally monitored through whole-blood trough concentrations. However, this approach may not accurately reflect lymphocyte tacrolimus levels, limiting its predictive value for allograft function and rejection. Monitoring tacrolimus levels in peripheral blood mononuclear cells (PBMCs) offers a potentially more precise alternative, though its clinical value remains unclear. This study aimed to compare tacrolimus intra-patient variablity (IPV), allograft function, and de novo donor-specific anti-HLA antibody (dnDSA) status between PBMC-based and whole-blood tacrolimus monitoring methods to assess whether PBMC monitoring provides greater clinical utility.Methods: This single-center, prospective, observational, non-interventional study enrolled kidney transplant recipients between November 2021 and February 2023. At six follow-up time points after transplantation (Day 7, Day 14, Month 1, Month 3, Month 6, and Month 12), tacrolimus levels in PBMCs and whole blood were measured, and IPVs in both matrices were calculated. Pearson’s or Spearman’s correlation analyses were used to evaluate (1) the relationship between tacrolimus levels in PBMCs and whole blood, (2) their association with allograft function, and (3) the correlation of tacrolimus IPV with allograft function and dnDSA status.Results: A total of 60 kidney transplant recipients were included. Within 1-year post-transplantation, the PBMC tacrolimus levels were 3.6% of whole-blood levels (P < 0.01). Tacrolimus levels in PBMCs and whole blood showed positive correlations across six-time points, with statistically significant correlations on Day 7, Day 14, Month 3, and Month 6 (P < 0.05). Notably, PBMC tacrolimus levels demonstrated stronger associations with creatinine clearance and estimated glomerular filtration rate at multiple timepoints compared to whole-blood measurements. Patients with dnDSA exhibited significantly higher IPV in PBMC tacrolimus levels than dnDSA-negative counterparts (P < 0.05), a pattern not observed in whole-blood analysis.Conclusion: Monitoring tacrolimus levels and IPVs in PBMCs provides greater insight into allograft function and dnDSA status than whole-blood measurements. These findings suggest that PBMC-based tacrolimus monitoring may enhance clinical value in managing kidney transplant recipients.

10 April 2026 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
RGRui Ge
Rui Ge
XNXinwen Nian
Xinwen Nian
BLBenjuan Liu
Benjuan Liu
YYYang Yunyun
Yang Yunyun
ZWZhuo Wang
Zhuo Wang
Effective treatment of bacterial prostatitis is limited by poor antibiotic penetration into prostatic tissue due to anatomical and physiological barriers, including the blood-prostate barrier, pH-dependent ion trapping, and protein binding. A systematic review was conducted to evaluate the intraprostatic pharmacokinetics of antibiotics. PubMed, Embase, and Medline were searched up to December 2024. In total, 44 studies reporting antibiotic concentrations in serum, prostate tissue, or prostatic fluids were included. Prostate tissue-to-serum ratios (PT/S) and pharmacokinetic parameters were analyzed to assess prostate penetration. A total of 44 studies were included. Fluoroquinolones consistently demonstrated favorable intraprostatic penetration (PT/S ≥ 1), supporting their role as first-line agents. Trimethoprim-sulfamethoxazole (TMP-SMX) showed moderate penetration driven primarily by trimethoprim, while macrolides and tetracyclines exhibited variable but measurable distribution. Most β-lactams penetrated poorly into non-inflamed prostate tissue, although selected cephalosporins achieved moderate concentrations in acute inflammatory settings. Fosfomycin showed variable intraprostatic exposure, indicating that tissue diffusion does not uniformly translate into clinical efficacy, particularly in chronic disease. Antibiotic efficacy in prostatitis is strongly influenced by intraprostatic pharmacokinetics rather than drug class alone. Integrating physicochemical properties, disease subtype, and clinical guideline recommendations is essential for rational antibiotic selection and optimized treatment strategies.